drugset / Trial / NCT04408599
A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This research study is studying a new drug, NC410, as a possible treatment for advanced or metastatic solid tumors.
Timeline
- Start
- 2020-06-10
- Primary completion
- 2023-07-06
- Completion
- 2023-07-06
Outcome
Outcome not reported
Stopped: “Upon completion of the Phase 1 portion of the NC410 monotherapy trial, NextCure focused efforts on a combination trial of NC410 in solid tumors.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NC410 | Monoclonal antibody | 3 mg | Intravenous |
| Subject | NC410 | Monoclonal antibody | 6 mg | Intravenous |
| Subject | NC410 | Monoclonal antibody | 15 mg | Intravenous |
| Subject | NC410 | Monoclonal antibody | 30 mg | Intravenous |
| Subject | NC410 | Monoclonal antibody | 60 mg | Intravenous |
| Subject | NC410 | Monoclonal antibody | 100 mg | Intravenous |
| Subject | NC410 | Monoclonal antibody | 200 mg | Intravenous |